CD-19-directed immunotherapy resistance mechanisms of B-precursor acute lymphoblastic leukemia
Immunotherapy is the most rapidly evolving field in clinical malignant hematology. Targeting of the B-lineage surface antigen CD19 in B-lineage acute lymphoblastic leukemia and B-cell lymphoma is a story of great success. Recently two approaches of CD19 immunotargeting were approved for clinical app...
Saved in:
| Main Authors: | E. V. Glukhanyuk, A. V. Stepanov, A. M. Popov, M. A. Maschan |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-01-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/316 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Struggle Between Chimeric Antigen Receptor T-Cell Therapy and Neurological Complications in Acute Lymphoblastic Leukemia Treatment
by: Norwin Kubick, et al.
Published: (2025-05-01) -
Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies
by: Xiaoshuang Yuan, et al.
Published: (2025-05-01) -
Extramedullary relapse of acute lymphoblastic leukemia treated with a CAR-T cell therapy bridge to unrelated cord blood transplantation: a case report and review of the literature
by: Huibo Li, et al.
Published: (2025-08-01) -
Immunophenotypic investigation of infant acute lymphoblastic leukemia
by: A. M. Popov, et al.
Published: (2014-07-01) -
Autotransplantation of T-lymphocytes as a tool for antigen-specific immunotherapy of oncological diseases
by: A. Yu. Lupatov, et al.
Published: (2018-09-01)